Interferon beta-1b vs peginterferon beta-1a
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Sclerosis
Shared mechanisms: Interferon beta receptor (type I IFN signaling) · Type I interferon receptor · full Multiple Sclerosis pipeline
Interferon beta-1b
Marketed by Bayer
NCT00099502 · Phase 3 · completed
The study was a large randomized, triple-blind, active-controlled trial comparing two interferon beta-1b doses with Copaxone, with relapse hazard as the clinical primary endpoint. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Reported efficacy
Time to Clinically Definite Multiple Sclerosis (CDMS) Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With CDMS at Selected Points in Time (up to 60 months after start of treatment); Time to Confirmed Expanded Disability Status Scale (EDSS) Progression Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With Confirmed EDSS Progression at Selected Points in Time (up to 60 months after start of treatment); Functional Assessment of Multiple Sclerosis (FAMS) Trial Outcome Index (TOI) at Month 60 (60 months after start of treatment): Time to Clinically Definite Multiple Sclerosis (CDMS) Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With CDMS at Selected Points in Time (up to 60 months after start of treatment): Initial IFNB-1b (Interferon Beta-1b) — Kaplan-Meier estimate at year 2: 26.9 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 3: 36.7 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 5: 46.2 cum. percentage of particip. with CDMS vs Initial Placebo — Kaplan-Meier estimate at year 2: 45 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 3: 51.2 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 5: 57.3 cum. percentage of particip. with CDMS (mixed)
Result source: NCT00185211
peginterferon beta-1a · Plegridy
Marketed by Biogen
NCT00906399 · Phase 3 · completed
This was a large, randomized, triple-blind, placebo-controlled trial with 1,516 participants. Its primary clinical endpoint, annualized relapse rate at one year, was statistically significantly lower with both peginterferon beta-1a schedules than with placebo (p=0.0007 for every 2 weeks and p=0.0114 for every 4 weeks).
Next expected readout: May 2027 · NCT03958877 (registry estimate)
Reported efficacy
Annualized Relapse Rate (ARR) at 1 Year: Annualized Relapse Rate (ARR) at 1 Year (1 Year): Year 1: Peginterferon Beta-1a Q4W 0.288 relapses per person-years (95% CI 0.234 to 0.355) | Year 1: Peginterferon Beta-1a Q2W 0.256 relapses per person-years (95% CI 0.206 to 0.318) vs Year 1: Placebo 0.397 relapses per person-years (95% CI 0.328 to 0.481) (met)
Result source: NCT00906399
Results for Multiple Sclerosis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Interferon beta-1b | peginterferon beta-1a |
|---|---|---|
| Annualised relapse rate | 0.2 vs 0.3−0.1 vs placeboNCT00185211 | 0.3 vs 0.4−0.1 vs placeboNCT009063992 other results
|
| Free of 3-month confirmed disability progression (%) | —Not posted · NCT00099502 | —Trial running · NCT03958877 |
| New or enlarging T2 lesions | —Not posted · NCT00099502 | 7.9 vs 10.9−3 vs placeboNCT009063991 other result
|
Annualised relapse rate
- Interferon beta-1b
- 0.2 vs 0.3−0.1 vs placeboNCT00185211
- peginterferon beta-1a
- 0.3 vs 0.4−0.1 vs placeboNCT00906399
2 other results
- 0.3 vs 0.4 NCT00906399
- 0 vs 0.5 NCT03870763
Free of 3-month confirmed disability progression (%)
- Interferon beta-1b
- —Not posted · NCT00099502
- peginterferon beta-1a
- —Trial running · NCT03958877
New or enlarging T2 lesions
- Interferon beta-1b
- —Not posted · NCT00099502
- peginterferon beta-1a
- 7.9 vs 10.9−3 vs placeboNCT00906399
1 other result
- 3.6 vs 10.9 NCT00906399
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety
Coverage. Interferon beta-1b: 6 of 6 rows · peginterferon beta-1a: 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Interferon beta-1b Rows use multiple source trials | peginterferon beta-1a Rows use multiple source trials |
|---|---|---|
| Annualized Relapse event rate · per year No placebo or comparator arm | 0.38 per year @ 24wka,b,c NCT00370071 · Phase 3 · registry result, not featured evidence | 0.142 per yearQ2Wd,a,b,c NCT01332019 · Phase 3 · monotherapy show 1 more dose0.189 per yearQ4W NCT01332019 · Phase 3 · monotherapy |
| New Active Lesion event count · lesions No placebo or comparator arm | -1.5 lesions @ 24wka,b,e NCT00370071 · Phase 3 · registry result, not featured evidence | 3.9 lesions @ 96wkQ2Wd,a,b,e NCT01332019 · Phase 3 · monotherapy show 1 more dose9 lesions @ 96wkQ4W NCT01332019 · Phase 3 · monotherapy |
| Dropout rate | 7.2%f NCT00185211 · Phase 3 · monotherapy show 1 more result5.1% NCT00370071 · Phase 3 · registry result, not featured evidence | 14.8%every 2 weeksg NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 show 9 more results12.6%every 4 weeks NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 —every 2 weeks NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 —every 4 weeks NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 50%125 µg NCT03870763 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 18.4%BIIB017 Plus Current FLS Therapy NCT01939002 · Phase 3 · combination 18.4%BIIB017 Plus Naproxen NCT01939002 · Phase 3 · combination 22.3%Q2W NCT01332019 · Phase 3 · monotherapy 21.3%Q4W NCT01332019 · Phase 3 · monotherapy 14%125 μg NCT02587065 · Phase 4 · registry result, not featured evidence |
| Discontinued due to AEs | 3.1%f NCT00185211 · Phase 3 · monotherapy show 1 more result— NCT00370071 · Phase 3 · registry result, not featured evidence | 4.7%every 2 weeksg NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 show 9 more results4.4%every 4 weeks NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 —every 2 weeks NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 —every 4 weeks NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 —125 µg NCT03870763 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 12.6%BIIB017 Plus Current FLS Therapy NCT01939002 · Phase 3 · combination 13.3%BIIB017 Plus Naproxen NCT01939002 · Phase 3 · combination 4%Q2W NCT01332019 · Phase 3 · monotherapy 2.5%Q4W NCT01332019 · Phase 3 · monotherapy 7.3%125 μg NCT02587065 · Phase 4 · registry result, not featured evidence |
| Serious AEs | 20.9%f NCT00185211 · Phase 3 · monotherapy show 1 more result0% NCT00370071 · Phase 3 · registry result, not featured evidence | 10.7%every 2 weeksg NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 show 9 more results14%every 4 weeks NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 8.9%every 2 weeks NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 15.3%every 4 weeks NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 0%125 µg NCT03870763 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 3.9%BIIB017 Plus Current FLS Therapy NCT01939002 · Phase 3 · combination 6.1%BIIB017 Plus Naproxen NCT01939002 · Phase 3 · combination 16.6%Q2W NCT01332019 · Phase 3 · monotherapy 21.6%Q4W NCT01332019 · Phase 3 · monotherapy 0%125 μg NCT02587065 · Phase 4 · registry result, not featured evidence |
| Most frequent reported AEs | f injection site reaction 55.8% (placebo 40.3%) flu syndrome 52.1% (placebo 51.1%) multiple sclerosis 38.4% (placebo 46.6%) NCT00185211 · Phase 3 · monotherapy show 1 more resultinfluenza like illness 41% hepathic function abnormal 17.9% headache 15.4% NCT00370071 · Phase 3 · registry result, not featured evidence | every 2 weeksg injection site erythema 61.4% (placebo 6.6%) influenza like illness 46.4% (placebo 12.6%) pyrexia 44.2% (placebo 15%) NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 show 9 more resultsevery 4 weeks injection site erythema 56.4% (placebo 6.6%) influenza like illness 46.8% (placebo 12.6%) pyrexia 43.6% (placebo 15%) NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 every 2 weeks injection site erythema 48.4% (placebo 6.6%) influenza like illness 43.8% (placebo 12.6%) pyrexia 31.1% (placebo 15%) NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 every 4 weeks injection site erythema 48.1% (placebo 6.6%) influenza like illness 45.3% (placebo 12.6%) pyrexia 31.4% (placebo 15%) NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 125 µg headache 66.7% (placebo 33.3%) abdominal pain 33.3% (placebo 0%) anxiety 16.7% (placebo 0%) NCT03870763 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 injection site erythema 44.7% injection site reaction 22.3% injection site pruritus 11.7% NCT01939002 · Phase 3 · combination injection site erythema 34.7% injection site reaction 21.4% influenza like illness 13.3% NCT01939002 · Phase 3 · combination Q2W influenza like illness 42.8% injection site erythema 41% headache 29.4% NCT01332019 · Phase 3 · monotherapy Q4W influenza like illness 44.2% injection site erythema 42% multiple sclerosis relapse 29.3% NCT01332019 · Phase 3 · monotherapy 125 μg influenza like illness 14.5% injection site reactions 5.2% pyrexia 5.2% NCT02587065 · Phase 4 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cThe assessment timepoint is not available for both results.
- dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- eAssessment timepoints differ: 96 weeks versus 24 weeks.
- fPopulation comparability has not been reviewed for these studies.
- gPopulation comparability has not been reviewed for 5 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Interferon beta-1b
show 2 more results
show 2 more results
show 1 more result
+ 6 further endpoints in the CSV export.
peginterferon beta-1a
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 3 more results
show 3 more results
show 1 more result
show 1 more result
show 1 more result
+ 58 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Interferon beta-1b's landscape · peginterferon beta-1a's landscape